Published in Cancer on January 01, 1974
Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? Br J Cancer (1998) 1.39
Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest (1979) 1.37
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer (1989) 1.21
Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. Br J Cancer (1980) 1.13
Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother (1983) 1.05
Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer (1992) 1.01
Cytotoxicity of adriamycin to tumour cells in vivo and in vitro. Br J Cancer (1980) 1.00
Systolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemia. Br Med J (1979) 0.96
Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. Br Med J (Clin Res Ed) (1981) 0.95
Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One (2012) 0.93
Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open (2016) 0.91
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs (2000) 0.86
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). Br J Cancer (1998) 0.86
Cytofluorescence localization of adriamycin in the nervous system. III. Distribution of the drug in the brain of normal adult mice after intraventricular and arachnoidal injections. Acta Neuropathol (1982) 0.81
Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J Cachexia Sarcopenia Muscle (2016) 0.81
Anthracycline cardiotoxicity and acute myelogenous leukaemia. Br Med J (1977) 0.80
Impact of Doxorubicin Treatment on the Physiological Functions of White Adipose Tissue. PLoS One (2016) 0.79
Functions of yeast helicase Ssl2p that are essential for viability are also involved in protection from the toxicity of adriamycin. Nucleic Acids Res (2004) 0.78
An evaluation of hepatic extraction and clearance of doxorubicin. Br J Cancer (1995) 0.77
Drug overdose--a hidden hazard of obesity. J R Soc Med (1987) 0.77
Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol (2014) 0.75
Caspase mediated synergistic effect of Boswellia serrata extract in combination with doxorubicin against human hepatocellular carcinoma. Biomed Res Int (2014) 0.75
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Sci Rep (2017) 0.75
Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. Invest New Drugs (1990) 0.75
Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol (2017) 0.75
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. Ann Intern Med (1973) 3.81
Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med (1982) 2.97
Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med (1972) 2.75
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood (2000) 2.65
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med (1977) 2.52
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol (1989) 2.36
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol (1995) 2.33
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res (1978) 2.24
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood (2001) 2.20
Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus (2001) 2.04
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol (2012) 1.81
Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med (1974) 1.77
NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A (1979) 1.75
Phase I clinical and pharmacokinetic study of taxol. Cancer Res (1987) 1.74
Bis-benzimidazole anticancer agents: targeting human tumour helicases. Anticancer Drug Des (1999) 1.66
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res (1974) 1.62
Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg (1990) 1.59
Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. Cancer (1990) 1.59
Biological and biochemical properties of Phaseolus vulgaris isolectins. J Biol Chem (1977) 1.55
Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem (1984) 1.54
Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med (1975) 1.53
Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med (1981) 1.53
Purification of the phytohemagglutinin family of proteins from red kidney beans (Phaseolus vulgaris) by affinity chromatography. Biochim Biophys Acta (1975) 1.52
Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J Infect Dis (1974) 1.51
Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg (1986) 1.50
Prolonged venous access for chemotherapy by means of the Hickman catheter. Cancer (1983) 1.49
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer (1994) 1.46
Adriamycin cardiomyopathy--risk factors. Cancer (1977) 1.46
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin Cancer Res (2000) 1.45
Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol (1991) 1.44
Factors affecting survival in nocardiosis. Am Rev Respir Dis (1973) 1.44
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol (1987) 1.44
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood (2000) 1.41
Anticipation in familial plasma cell dyscrasias. Br J Haematol (1998) 1.41
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med (1980) 1.40
Rectal abscesses in cancer patients. Lancet (1972) 1.40
Acute promyelocytic leukemia: another pseudoleukemia? Blood (1990) 1.38
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer (1997) 1.36
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res (1977) 1.36
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol (1997) 1.34
Clinical presentation of infection in granulocytopenic patients. Arch Intern Med (1975) 1.33
Clinical significance of serum and urinary muramidase activity in leukemia and other hematologic malignancies. Am J Med (1969) 1.33
Granulocytic sarcoma (chloroma). Blood (1970) 1.33
Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol (1992) 1.33
Factors effecting remission and survival in adult acute nonlymphocytic leukemia (ANLL). Medicine (Baltimore) (1970) 1.32
Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Antimicrob Agents Chemother (1978) 1.31
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer (1999) 1.31
Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. Am J Med (1979) 1.31
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol (1999) 1.29
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery (1994) 1.28
Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood (1989) 1.28
Infection in acute leukemia patients receiving oral nonabsorable antibiotics. Antimicrob Agents Chemother (1978) 1.27
Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. Cancer Chemother Rep (1970) 1.26
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol (1999) 1.25
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital. JAMA (1976) 1.25
Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol (1977) 1.22
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol (1996) 1.22
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer (1973) 1.21
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep (1977) 1.21
Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med (1974) 1.20
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA (1988) 1.20
Torulopsis glabrata infections in patients with cancer. Increasing incidence and relationship to colonization. Am J Med (1976) 1.20
Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther (1973) 1.19
Hepatic stimulator substance: physicochemical characteristics and specificity. Am J Physiol (1982) 1.18
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol (1994) 1.17
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol (2001) 1.17
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol (1990) 1.17
Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol (1987) 1.17
Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes. Science (1976) 1.16
The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther (1971) 1.16
A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med (1981) 1.15
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol (1995) 1.15
Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos (1976) 1.14
Myxoid liposarcoma. Experience with chemotherapy. Cancer (1994) 1.13
Increased incidence of brain metastases in sarcoma patients. Cancer (1980) 1.13
Radiation-related pericarditis. Am J Cardiol (1975) 1.13